MARKET

BCYC

BCYC

Bicycle Therapeutics Limited
NASDAQ
6.87
+0.10
+1.48%
Opening 10:54 12/19 EST
OPEN
6.80
PREV CLOSE
6.77
HIGH
7.02
LOW
6.73
VOLUME
37.56K
TURNOVER
--
52 WEEK HIGH
17.04
52 WEEK LOW
6.03
MARKET CAP
476.56M
P/E (TTM)
-1.8973
1D
5D
1M
3M
1Y
5Y
1D
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 3d ago
Bicycle Therapeutics Secures Long-Term Nuclear And Industry Partnerships To Support 212Pb Radiopharmaceutical Development And Commercial Supply
Benzinga · 3d ago
Bicycle Therapeutics Signs 15-Year Uranium Supply Contract with UK Nuclear Decommissioning Authority
Reuters · 3d ago
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Barchart · 3d ago
Weekly Report: what happened at BCYC last week (1208-1212)?
Weekly Report · 4d ago
Weekly Report: what happened at BCYC last week (1201-1205)?
Weekly Report · 12/08 09:11
Weekly Report: what happened at BCYC last week (1124-1128)?
Weekly Report · 12/01 09:10
Bicycle Therapeutics Price Target Announced at $10.00/Share by Truist Securities
Dow Jones · 11/24 18:04
More
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Webull offers Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ: BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.